SHORT REPORT

The impact of exercise on growth factors (VEGF and FGF2): results from a 12-month randomized intervention trial

Darren R. Brenner^{1,2,3*}, Yibing Ruan¹, Scott C. Adams⁴, Kerry S. Courneya⁴ and Christine M. Friedenreich^{1,2,3}

Abstract

Background: Vascular endothelial growth factor (VEGF) and Fibroblast growth factor-2 (FGF2) are angiogenic cytokines in normal tissues and tumors. Evidence suggests that increased growth factor expression in adipose tissue leads to improved vascularity and decreased hypoxia, fibrosis, and inflammation, which may, in turn, reduce post-menopausal breast cancer risk.

Objective: We investigated whether or not exercise had dose-response effects on levels of plasma VEGF and FGF2 in postmenopausal women.

Methods: Four hundred previously inactive but healthy postmenopausal women aged 50–74 years of age were randomized to 150 or 300 min per week of aerobic exercise in a year-long exercise intervention. VEGF and FGF2 were measured from fasting serum samples with a custom-plex multiplex assay.

Results: A high compared to moderate volume of aerobic exercise did not cause chronic changes in plasma VEGF or FGF2 levels in intention-to-treat or per-protocol analyses.

Conclusions: We did not detect differences in growth factor levels related to increasing doses of exercise. It is unlikely that changes in VEGF and FGF2 levels mediate the reduction in risk of post-menopausal breast cancer development in associated with increased levels of exercise.

Trial registration: Clinicaltrials.gov identifier: NCT01435005.

Keywords: Aerobic exercise, Growth factors, Breast Cancer, Intervention trial, Randomized controlled trial

Introduction

Regular lifetime exercise has been consistently associated with a reduced risk of developing postmenopausal breast cancer [1]. Several mechanisms underlying the impact of exercise have been identified, including reductions in adiposity, sex hormone levels, insulin resistance and chronic inflammation [1]. These pathways explain some portion of the association; however, additional mechanisms require identification and further investigation.

One additional mechanism of interest is the impact of exercise on growth factors known to drive cell proliferation

* Correspondence: Darren.Brenner@ucalgary.ca

²Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada (VEGF) is a potent angiogenic cytokine in normal tissues and tumors. It has been shown to stimulate endothelial cell proliferation in vitro and induce angiogenesis in vivo [3]. Fibroblast growth factors are a family of growth factors related to a broad range of physiologic functions including angiogenesis and epithelial proliferation [4]. Fibroblast growth factor-2 (FGF2) is an interesting candidate in breast cancer pathology as a common single nucleotide polymorphism in the gene has been associated with breast cancer risk in large studies among Western populations [5].

and tissue growth [2]. Vascular endothelial growth factor

In a previous investigation from the Breast cancer and Exercise Trial in Alberta (BETA), we observed that higher levels of activity were associated with reduced body fat [6]. Unhealthy fat pad expansion is characterized by inadequate vascularization and hypoxia – leading to increased fibrosis, inflammation and insulin resistance

© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.





Open Access

¹Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Full list of author information is available at the end of the article

⁻

Group	n	Baseline		6 Months		12 Months		Treatment Effe	ct	Between-
		Geo-metric Mean ^a	95% CI	Geo-metric Mean	95% CI	Geo-metric Mean	95% CI	Ratio of High/ Moderate ^b	95% CI	Group P ^c
Intention-to-1	reat									
FGF2										
High	195	121.3	114.4–128.5	116.1	110.1-122.4	123.3	117.7–129.2	0.98	0.94-1.02	0.28
Moderate	191	118.8	111.9–126.2	122.9	116.2-130.0	120.1	113.1–127.6			
VEGF										
High	195	62.3	55.1-70.4	58.5	51.7-66.3	58.6	51.3-66.9	0.94	0.86-1.02	0.15
Moderate	191	64.9	57.2–73.6	63.6	55.7–72.6	67.3	58.9–76.9			
Per-protocol	d									
FGF2										0.64
High	80	119.8	110.8–129.4	116.0	107.3-125.3	121.2	113.5–129.4	1.02	0.95-1.10	
Moderate	58	112.6	100.0-126.7	113.9	101.9–127.3	109.6	98.3-122.2			
VEGF										0.74
High	80	60.6	50.8-72.3	60.6	50.0-73.4	58.0	47.6-70.7	0.98	0.84-1.13	
Moderate	58	70.3	54.2-91.0	64.9	49.9–84.6	74.0	56.9-96.3			

Table 1 Intention-to-treat and per-protocol analysis of FGF2 and VEGF concentrations between high and moderate volume exercise groups in BETA (n = 386)

a. Geometric mean of FGF2 and VEGF was in the unit of pg/mL

b. The geometric mean ratios were estimated from least square means for the difference in treatment effect between high and moderate volume exercisers averaged across the entire study period adjusted for the baseline values and then back log-transformed

c. P value corresponds to the null hypothesis that the ratio of treatment effect between high- and moderate-volume groups equals 1 against the 2sided alternative hypothesis

d. Women assigned to the moderate-volume group were adherent if they completed 90 to 100% of the exercise prescription (mean, 135–150 min/wk), weeks 13 to 52 at full prescription; women assigned to the high-volume group were adherent if they completed at least 90% of the exercise prescription (mean, $\geq 270 \text{ min/wk}$), weeks 13 to 52 at full prescription

[7]. We hypothesized that exercise-induced change in adipose tissue vascular remodeling may account for some of the observed exercise-related reduction in postmenopausal breast cancer risk. As part of ancillary investigations from BETA to evaluate novel mechanisms relating exercise to breast cancer risk, we investigated whether a higher versus a more moderate volume of exercise would lead to differential changes in VEGF and FGF2 levels.

Materials and methods

BETA study design and eligibility criteria have been described elsewhere [8]. Briefly, we randomized 400 postmenopausal women, aged 50–74 years old, who were previously inactive but otherwise healthy to 150 (MOD-ERATE) or 300 (HIGH) minutes/week of aerobic exercise at 65–75% of maximal heart rate reserve for 12 months. Participants completed three supervised sessions and two unsupervised sessions per week, with the HIGH volume exercise group completely exercise sessions that were twice as long as the MODERATE volume group. During exercise sessions, any aerobic activity that raised that participants' heart rates to their target heart rate zones was permitted.

Fasting blood samples were drawn from study participants at baseline, 6 and 12 months, after a 24-h complete abstinence from exercise and alcohol intake and at least 10 h since the last food intake. FGF2 and VEGF levels in plasma were quantified using a customplex Human Circulating Cancer Biomarker Multiplex Assay. The multiplex assays were performed at Eve Technologies (Calgary, AB, Canada) using the Bio-Plex™ 200 system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The detection limits for FGF2 and VEGF in this assay were 3.6 and 6.4 pg/mL, respectively. The interand intra-assay coefficients of variation (CV) were 6.3 and 7.9% for FGF2, and 10.2 and 12% for VEGF, which are below or comparable to other CVs using the Bio-Plex platform [9]. All lab personnel were blinded to the intervention assignment. Each participant's samples at different time points were analyzed in the same batch and each batch included an equal number of MODER-ATE and HIGH blood samples.

Changes in concentrations of growth factors in the two intervention groups were compared in an intentionto-treat (ITT) analysis using linear mixed models that accounted for repeated measures of FGF2 and VEGF at 6 and 12 months, adjusting for baseline levels of the biomarker as a covariate. Treatment effect ratios (TERs) were calculated from these models and denoted the HIGH: MODERATE ratio of geometric mean biomarker levels over 12 months (reflecting changes from baseline

: 38	
Ш	
2	
<	
BET/	
B	
C	
ğ	
2	
gra	
0,	
cise	
Xe	
Û	
é	
5	
-	
Ś	
te	
Ľ.	
B	
ŏ	
E	
σ	
ЧЦ	
č	
đ	
Ē	
E	
ă	
Ž	
bet	
Ц	
ЪĜ	
\leq	
p	
ar	
FZ	
Ы	
ŭ	
.⊆	
S	
g	
Ĕ	
ha	
of	
ses	
Se	
aly	
a	
0	
Ξ	
tratif	
Št.	
ble 2	
le le	

	n 6 months percent	12 months percent	Treatment effect ^a		Between-
thigh intensity ^c Me prescribed MODERATE 17 HIGH 16 HIGH 44 MODERATE 116 HIGH 36 HIGH 23 HIGH 75 HIGH 73 HIGH 73 HIGH 93 Level ^e 22 m/kg min MODERATE 93 HIGH 93 ADDERATE 93 HIGH 93 MODERATE 93 HIGH 93 MODERATE 93 HIGH 93 MODERATE 93 HIGH 93 MODERATE 93 HIGH 93 HIGH 93 MODERATE 93 HIGH 93 MODERATE 93 HIGH 93 MODERATE 116 HIGH 36 HIGH 112 HIGH 112 HI	cnange irom paseline	cnange irom paseline	Ratio of HIGH:MOD	95% CI	group r
thigh intensity ^c More Prescribed MODERATE 17 HIGH 17 HIGH 13 HIGH 36 HIGH 36 HIGH 36 HIGH 36 HIGH 121 HIGH 75 HIGH 75 HIGH 75 HIGH 74 C MODERATE 93 HIGH 93 HIGH 93 HIGH 93 HIGH 93 HIGH 93 HIGH 93 HIGH 93 MODERATE 94 HIGH 93 HIGH 94 HIGH 94 HIGH 95 HIGH 95 HIGH 95 HIGH 17 HIGH 95 HIGH 17 HIGH					
% prescribed MODERATE 17 % prescribed MODERATE 41 % prescribed MODERATE 41 % prescribed MODERATE 41 MODERATE MODERATE 41 MODERATE 116 116 MODERATE 116 75 MODERATE MODERATE 74 MODERATE 74 74 Level MODERATE 93 Zzm/kg min MODERATE 93 MODERATE MODERATE 93 Zzm/kg min MODERATE 94 MODERATE 97 97 Stkg MODERATE 97 MODERATE 96 96 MODERATE 116 36 MODERATE					
HGH 41 % prescribed MODERATE 41 HGH 36 41 HGH 36 41 HGH 36 41 D MODERATE 116 D MODERATE 121 D MODERATE 75 HIGH 74 74 level ^e 75 93 Level 75 93 Jakg MODERATE 74 Joudy fat ^f 74 93 Joudy fat ^f MODERATE 93 Job fact ^f MODERATE 94 Job fact ^f MODERATE 94 Job fact ^f MODERATE 96 Job fact ^f MODERATE 96 MODERATE 96 97 Job fact ^f MODERATE 96 MODERATE 96 97 Job faccribed MODERATE 96 Job faccribed MODERATE 96 HGH		4.9	1.03	0.91-1.17	0.62
% prescribed MODERATE 41 HGH 36 HGH 36 HGH 116 MODERATE 116 HGH 73 HGH 74 Level ^e 74 2ml/kg min MODERATE 74 Level ^e MODERATE 93 21ml/kg min MODERATE 93 Ady fat ^f MODERATE 93 Zaml/kg min MODERATE 94 Zaml/kg min MODERATE 93 JZ kg MODERATE 93 Ody fat ^f MODERATE 93 JZ kg MODERATE 94 MODERATE 94 94 JZ kg MODERATE 94 MODERATE 96 97 JZ kg MODERATE 96 MODERATE 96 97 MODERATE 96 97 JS kg prescribed MODERATE 96 MODERATE 96 97 MODERATE 96 97 MODERATE 96 97 MODERATE 96 97 MODERATE 96 96 MODERATE 96 96 <td< td=""><td></td><td>0.3</td><td></td><td></td><td></td></td<>		0.3			
HIGH 36 MODERATE 116 HIGH 121 HIGH 121 HIGH 75 HIGH 74 Level ^e 74 Level 74 Job fat ^f MODERATE Job fat ^f 93 Ody fat ^f MODERATE Job fat ^f 93 Job fat 116 Job MODERATE 116 Job MODERATE 116		-5.6	1.01	0.92-1.12	0.78
) MODERATE 116 HIGH 121 HIGH 121 HIGH 75 HIGH 74 Level ^e 75 HIGH 74 C2m/kg min MODERATE 93 HIGH 99 MODERATE 98 HIGH 99 37 kg MODERATE 94 HIGH 96 HIGH 96 HIGH 96 HIGH 96 HIGH 96 HIGH 96 HIGH 17 HIGH 17 MODERATE 11 HIGH 36 HIGH 17 HIGH 17 MODERATE 11 HIGH		2.3			
30 MODERATE 116 30 HIGH 121 30 MODERATE 75 31 HIGH 74 32 MODERATE 75 30 MODERATE 74 31 HIGH 74 32 J2/J m/kg min MODERATE 27.2 m/kg min MODERATE 93 29.7 kg MODERATE 94 20% prescribed MODERATE 94 30 MODERATE 17 30 MODERATE 116 30 MODERATE 116					
30 HIGH 121 30 MODERATE 75 HIGH 74 74 HIGH 74 74 Jase level ^e MODERATE 93 272 m/kg min MODERATE 93 297 kg MODERATE 93 297 kg MODERATE 94 208 prescribed MODERATE 11 30 MODERATE 116 30 MODERATE 116		6.8	0.99	0.94, 1.05	0.83
30 MODERATE 75 as, level * HIGH 74 272 m/kg min MODERATE 93 body fat * MODERATE 93 297 kg MODERATE 94 297 kg MODERATE 94 297 kg MODERATE 94 60% prescribed MODERATE 94 60% prescribed MODERATE 17 30 MODERATE 116 30 MODERATE 116		5.2			
MIGH 74 Level ^e 27.2 m/kg min MODERATE 93 27.2 m/kg min MODERATE 93 27.2 m/kg min MODERATE 94 body fat ^f MODERATE 94 body fat ^f 97 29.7 kg MODERATE 94 HIGH 99 29.7 kg MODERATE 94 HIGH 94 66% prescribed MODERATE 17 60% prescribed MODERATE 17 116 30 MODERATE 116 30 MODERATE 116 31 MODERATE 116 32 MODERATE 116 33 MODERATE 116 34 MODERATE 116 35 MODERATE 116 36 MODERATE 116 37 MODERATE 116 30 MODERATE 116 30 MODERATE 116 31 MODERATE 116 33 MODERATE 116 34 MODERATE 116 35 MODERATE 116 36 MODERATE 116 37 MODERATE 116 36 MODERATE 116 37 MODERATE 116 38 MODERATE 116 39 MODERATE 116 30 MODERATE 116		2.2	0.95	0.88, 1.02	0.13
ax level ^e 27.2 m/kg min MODERATE 93 27.2 m/kg min MODERATE 98 27.2 m/kg min MODERATE 98 body fat ^f 29.7 kg MODERATE 94 29.7 kg MODERATE 94 HIGH 99 dr high intensity 60% prescribed MODERATE 17 60% prescribed MODERATE 17 60% prescribed MODERATE 17 30 MODERATE 116 30 MODERATE 116		6.3			
272 m/kg min MODERATE 93 HIGH 98 272 m/kg min MODERATE 98 body fat ^f MODERATE 99 297 kg MODERATE 94 HIGH 99 297 kg MODERATE 94 HIGH 96 at high intensity MODERATE 17 at high intensity 17 60% prescribed MODERATE 17 HIGH 17 30 MODERATE 116 116 116 116 116 116 116 116 116 116					
HIGH 98 272 m/kg min MODERATE 98 body fat ^f HIGH 97 body fat ^f MODERATE 94 29.7 kg MODERATE 94 60% prescribed MODERATE 95 60% prescribed MODERATE 17 80 MODERATE 17 80 MODERATE 17 80 MODERATE 17 80 MODERATE 16 80 MODERATE 16 80 MODERATE 116 80 MODERATE 116 80 MODERATE 116		1.3	0.94	0.88, 1.00	0.05
272 m/kg min MODERATE 98 HIGH 97 body fat ^f 29.7 kg MODERATE 94 29.7 kg MODERATE 94 HIGH 99 GF 117 60% prescribed MODERATE 17 60% prescribed MODERATE 17 HIGH 24 80% prescribed MODERATE 17 HIGH 36 HIGH 115 30 MODERATE 116 30 MODERATE 116		8.2			
body fat ^f 29.7 kg MODERATE 94 29.7 kg MODERATE 94 29.7 kg MODERATE 99 29.7 kg MODERATE 94 60% prescribed MODERATE 17 at high intensity 16 at high intensity 17 60% prescribed MODERATE 17 80% prescribed 116 116 30 MODERATE 116 30 MODERATE 121		8.5	1.02	0.96, 1.08	0.56
body fat ^f 29.7 kg MODERATE 94 29.7 kg HIGH 99 29.7 kg MODERATE 97 29.7 kg HIGH 96 41 60% prescribed MODERATE 17 60% prescribed MODERATE 41 116 30 MODERATE 116 30 MODERATE 116 30 MODERATE 121		3.1			
29.7 kg MODERATE 94 HIGH 99 29.7 kg MODERATE 97 GF 97 GF 97 HIGH 96 60% prescribed MODERATE 17 60% prescribed MODERATE 17 60% prescribed MODERATE 17 30 MODERATE 116 HIGH 121 30 MODERATE 116					
29.7 kg HIGH 99 29.7 kg MODERATE 97 AlfGH 97 60% prescribed MODERATE 17 60% prescribed MODERATE 17 60% prescribed MODERATE 41 HIGH 36 30 MODERATE 116 30 MODERATE 121		5.5	1.02	0.96, 1.08	0.53
29.7 kg MODERATE 97 GF 96 d high intensity 96 at high intensity 96 60% prescribed MODERATE 17 60% prescribed MODERATE 17 80 MODERATE 116 916 930 MODERATE 116 930 MODERATE 121		3.0			
GF at high intensity 60% prescribed MODERATE 17 60% prescribed MODERATE 17 60% prescribed MODERATE 41 HIGH 36 HIGH 36 MODERATE 116 30 MODERATE 121		4.5	0.94	0.88, 1.00	0.04
GF at high intensity 60% prescribed MODERATE 17 60% prescribed MODERATE 17 80% prescribed MODERATE 41 90 MODERATE 116 90 MODERATE 121		8.5			
at high intensity 60% prescribed MODERATE 17 60% prescribed MODERATE 41 44 60% prescribed MODERATE 41 30 MODERATE 116 30 MODERATE 75					
60% prescribed MODERATE 17 60% prescribed HIGH 44 60% prescribed MODERATE 41 30 MODERATE 116 30 MODERATE 75					
HIGH 44 60% prescribed MODERATE 41 HIGH 36 30 MODERATE 116 HIGH 121 30 MODERATE 75		11.0	1.04	0.83-1.31	0.72
60% prescribed MODERATE 41 41 HIGH 36 30 MODERATE 116 HIGH 121 30 MODERATE 75		7.2			
HIGH 36 30 MODERATE 116 HIGH 121 30 MODERATE 25		3.2	06.0	0.73-1.10	0.28
30 MODERATE 116 HIGH 121 30 MODERATE 75		-16.8			
MODERATE 116 HIGH 121 MODERATE 75					
HIGH 121 MODERATE 75		6.0	06:0	0.80, 1.01	0.06
MODERATE 75	121 –10.4	-10.6			
	75 1.5	0.3	1.01	0.88, 1.15	0.90
HIGH 74 1.4		2.9			

Stratification	Prescribed exercise	L	6 months percent	12 months percent	Treatment effect ^a		Between_
variables	duration		change from baseline	change from baseline	Ratio of HIGH:MOD	95% CI	group P
VO _{2max} level							
< 27.2 ml/kg min	MODERATE	93	4.0	1.9	0.93	0.82, 1.06	0.29
	HIGH	98	-1.8	-6.7			
≥ 27.2 ml/kg min	MODERATE	98	-7.2	5.7	0.94	0.83, 1.06	0:30
	HIGH	97	-10.2	-5.1			
Total body fat							
< 29.7 kg	MODERATE	94	-7.7	4.5	0.92	0.80, 1.06	0.25
	HIGH	66	-9.1	-10.5			
≥ 29.7 kg	MODERATE	67	4.0	3.1	0.95	0.85, 1.06	0.39
	HIGH	96	-3.0	-0.3			

a. HIGH:MODERATE ratio of geometric means for biomarker levels over 12 months adjusted for biomarker level at baseline. A ratio < 1.0 indicates lower biomarker concentrations in the HIGH exercise group at 6 and 12 months; a ratio > 1.0 indicates lower biomarker concentrations in the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; and to 1.0 indicates no difference in biomarker concentrations between the HIGH and MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations in the MODERATE exercise group; a ratio equal to 1.0 indicates no difference in biomarker concentrations in the MODERATE

exercise groups b. P for testing the HIGH-MODERATE group difference over 12 months from the linear mixed model, adjusted for biomarker level at baseline c. Included n = 138 women for whom, across weeks 13–52 (at full prescription), average adherence in the exercise logs was 90–100% in the MODERATE group (135–150 min/week; n = 58) or $\ge 90\%$ in the HIGH group ($\ge 270 \text{ min/week}$; n = 80). Time at high intensity was defined as time exercising at an intensity of 60–80% heart rate reserve averaged for each participant over 52 weeks. Cut points for the stratified analysis were 60% of the prescribed durations i.e., 90 min/week in the MODERATE group and 180 min/week in the HIGH group

d. Body mass index at baseline

e. Cut point of the baseline VO_{2max} level for the stratified analysis were the median value for all study participants (MODERATE and HIGH group) f. Cut point of the baseline total body fat level for the stratified analysis were the median value for all study participants (MODERATE and HIGH group)

to 6 and 12 months). The ITT analysis was repeated by stratifying on a priori potential effect modifiers: baseline body mass index (BMI), baseline fitness (estimated VO_{2max}) and total percent body fat (full body dual X-ray absorptiometry scan).

A per-protocol analysis was undertaken for women who completed, on average, 90 to 100% of the exercise prescription for the MODERATE group or \ge 90% of prescription for the HIGH group from weeks 13–52.

Results

A total of 386 women completed the trial with no statistically significant difference in dropout between arms. Baseline characteristics and exercise adherence of the BETA study participants have been previously described [6]. We observed no statistically significant effects for increasing quartiles of exercise and change in circulating levels of VEGF or FGF2 with both groups combined (non-randomized, results not shown).

Results from linear mixed models suggested overall lower, but non-statistically significant group differences between baseline and 12 months for both FGF2 and VEGF for both arms of the trial. The HIGH group experienced slightly larger changes than the MODERATE group, but these changes were not clinically relevant (FGF2: TER 0.98, 95% CI 0.94–1.02; VEGF: TER 0.94, 95% CI 0.86–1.02; Table 1). Furthermore, the per-protocol analysis found essentially no differences between baseline and end of intervention effects with the TERs approximately equal to 1.0 for both biomarkers. Similarly, a per-protocol analysis stratified by exercise intensity, i.e., whether participants achieved 60% of the prescribed time in the target heart rate zone, showed no significant group differences in FGF2 and VEGF (Table 2).

Stratifying results by baseline BMI, VO_{2max}, and total body fat did not reveal any sub-group effects for VEGF (Table 2). Conversely, the result for FGF2 varied by baseline VO_{2max} and total body fat. Specifically, women with lower baseline physical fitness had an overall lower concentration of FGF2 in the HIGH group (TER 0.94, 95% CI 0.88, 1.00). However, this result was largely driven by the opposite direction of change at six months (8.2% increase in MODERATE group vs. 2.2% decrease in HIGH group). At 12 months, the HIGH group had a greater increase in FGF2 from baseline (8.2% vs 1.3% in MODERATE group). Likewise, the statistically significant TER for FGF2 observed among women with greater total body fat at baseline (TER 0.94; 95% CI 0.88, 1.00) was driven by the opposite direction of change at 6 months (5.8% increase in MODERATE group vs 2.2% decrease in HIGH group), while FGF2 showed a greater increase in HIGH group (8.5% vs 4.5% in MODERATE group).

Discussion

Growth factors (i.e., FGF2 and VEGF) and their receptors (FGF2R and VEGFR), have been implicated in breast cancer tumorigenesis [10, 11], progression [4, 11], and metastasis [4]. However, the expression of specific FGF2 and VEGF polymorphisms has also been shown to be protective against developing breast cancer [12, 13]. In BETA, the greatest increases in FGF2 expression were observed with HIGH volumes of exercise in those with lower baseline physical fitness and higher total body fat whereas, VEGF expression was unaltered.

Our findings may be partially explained by the followup assessment timing and the somewhat differential nature of each growth factor's pro-angio/arteriogenic action. In general, FGF2 and VEGF are important mediators of pro-angiogenic adaptations to repetitive exercise and act to increase tissue capillary density in response to hypoxic and inflammatory signaling [14]. However, it is well known that VEGF signaling is more central to supporting angiogenesis and neovascularization whereas FGF2 signaling plays a larger role in arteriogenesis and the maintenance of mature vessels [3, 15]. In general, chronically elevated growth factor levels may be considered pathologic – reflective of underlying tumor proliferative processes. However, in the context of exercise, transient growth factor increases can be viewed as normal physiologic hypoxia-driven adaptations - reflective of favorable vascular bed remodeling. While we would have expected to observe a transient increase in levels of these growth factors following the exercise intervention, in the context of the 12-month intervention within BETA, the six-month gap between follow-up assessments may have limited our ability to capture the transient spikes in the expression of these growth factors. Following an acute bout of exercise, the resulting increase in growth factor expression also appears to be transient - elevated after 7-10 days of training and returning to baseline after 28 days [16, 17].

In conclusion, high doses of supervised exercise did not impact levels of VEGF or FGF2. Additional mechanisms related to decreased breast cancer risk through altered adipose tissue require investigation.

Abbreviations

BETA: Breast cancer and Exercise Trial in Alberta; BMI: Body mass index; FGF2: Fibroblast growth factor-2; ITT: Intention-to-treat; TER: Treatment effect ratio; VEGF: Vascular endothelial growth factor

Acknowledgements

Calgary Study Coordinators were: Krista Carlson, Sana Fakih, Megan Farris, Quinn Harris, Sarah MacLaughlin, Erica Roberts, and Kristen Simone. Edmonton Study Coordinators were: Natalie Ilkiw, Ciara Kallal, and Dr. Amy Speed Andrews. Assistance with information sessions was provided in Calgary by Drs. Brigid Lynch and Fabiola Aparicio-Ting. Calgary Exercise Trainers were: Carrie Anderson, Alia Bharwani, Shannon Brown, Ashley Cuthbert, Sue Daniel, Julie Gowans, Margo Graham, Erin Korsbrek, Kathleen Kranenburg, Jessica Morrison, Jason Ng, Nicole Slot, Tania White, and Kaila Wright. Edmonton Exercise Trainers were: Arne Anderson, Lisa Belanger, Jennifer Crawford, Cindy Forbes, Alyssa Hindle, Corey Kuzik, Erin McGowan, Mary Norris, Janel Park, Julianne Symons, Linda Trinh, Stephanie Voaklander and Lynne Wong. Study recruiters were: Jennie Duke, Jasdeep Hayer, Trisha Kelly, Jasmine Lee, and Lilly Mah. Data entry was done by: Sinead Boyle, Barbara Mercer, Carla Quesnel and Trisha Kelly. Data management, including database creation, questionnaire design, data integrity and quality control, was done by: Dr. Steven Szarka, Farit Vakhetov, and Wendy Walroth. Qinggang Wang was responsible for the randomization procedures, sample size calculations and some data verification. The late Dr. Robert C. Millikan was a co-investigator on this trial and contributed to the study design and methods.

Funding

This work was supported by a Career Development Award in Prevention (#703917) from the Canadian Cancer Society Research Institute held by Dr. Brenner. Dr. Friedenreich holds a Health Senior Scholar Award from Alberta Innovates-Health Solutions and is the Alberta Cancer Foundation Weekend to End Women's Cancers Breast Cancer Chair. Dr. Courneya holds a Canada Research Chair in Physical Activity and Cancer.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Authors' contributions

DB assisted in data collection, interpretation and wrote the manuscript. YR completed the data analysis and assisted in interpretation and writing of the manuscript. SA assisted in interpretation and writing of the manuscript. CF and KC were responsible for the design and conduct of the study, data collection as well as writing and critical review of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Health Research Ethics Board of Alberta and all participants consented to participate.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. ²Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. ³Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Holy Cross Centre – Room 513C, Box ACB, 2210 – 2nd St. SW, Calgary, Alberta T2S 3C3, Canada. ⁴Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, Canada.

Received: 1 November 2017 Accepted: 19 April 2018 Published online: 24 June 2019

References

- Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer. 2010;46: 2593–604.
- McTiernan A, Sorensen B, Yasui Y, Tworoger SS, Ulrich CM, Irwin ML, et al. No effect of exercise on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomark Prev. 2005;14:1020–1.
- 3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389–96.
- Cao R, Ji H, Feng N, Zhang Y, Yang X, Andersson P, et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci. 2012;109:15894–9.

- Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013;45:353–361, 361e351–352.
- Friedenreich CM, Neilson HK, O'Reilly R, Duha A, Yasui Y, Morielli AR, et al. Effects of a high vs moderate volume of aerobic exercise on adiposity outcomes in postmenopausal women: a randomized clinical trial. JAMA Oncol. 2015;1:766–76.
- Sun K, Wernstedt Asterholm I, Kusminski CM, Bueno AC, Wang ZV, Pollard JW, et al. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci U S A. 2012;109:5874–9.
- Friedenreich CM, MacLaughlin S, Neilson HK, Stanczyk FZ, Yasui Y, Duha A, et al. Study design and methods for the breast Cancer and exercise trial in Alberta (BETA). BMC Cancer. 2014;14:919.
- Hermann N, Dreßen K, Schildberg FA, Jakobs C, Holdenrieder S. Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay. World Journal of Methodology. 2014;4:219–31.
- Beeghly-Fadiel A, Shu X-O, Lu W, Long J, Cai Q, Xiang Y-B, et al. Genetic variation in VEGF family genes and breast Cancer risk: a report from the Shanghai breast Cancer genetics study. Cancer Epidemiol Biomark Prev. 2011;20:33–41.
- Jain VK, Turner NC. Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer. Breast Cancer Res. 2012; 14:208.
- Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. The singlenucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat. 2012;133:769–78.
- Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.
- 14. Wagner PD. The critical role of VEGF in skeletal muscle angiogenesis and blood flow. Biochem Soc Trans. 2011;39:1556.
- Prior BM, Yang H, Terjung RL. What makes vessels grow with exercise training? J Appl Physiol. 2004;97:1119–28.
- Cuevas-Ramos D, Almeda-Valdés P, Meza-Arana CE, Brito-Córdova G, Gómez-Pérez FJ, Mehta R, et al. Exercise increases serum fibroblast growth factor 21 (FGF21) levels. PLoS One. 2012;7:e38022.
- Gustafsson T, Knutsson A, Puntschart A, Kaijser L, Nordqvist SA-C, Sundberg C, et al. Increased expression of vascular endothelial growth factor in human skeletal muscle in response to short-term one-legged exercise training. Pflugers Arch. 2002;444:752–9.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- · thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

